Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
The company said it plans to submit a Formal Dispute Resolution Request to the FDA over reproxalap for dry eye disease. Aldeyra also said it now expects operational cash runway into 2029 based on reported cash and cash equivalents of $45.1 million as of June 30, 2026.
Aldeyra plans an FDA Formal Dispute Resolution Request for reproxalap after a March 16, 2026 CRL, with OND meeting expected in Q4 2026. The company also guided operational cash runway into 2029.Material DetailsContext by AI AnalystThis is a regulatory appeal after multiple CRLs for reproxalap, sign…
Aldeyra Therapeutics announced its intent to submit a formal dispute resolution request for reproxalap to treat dry eye disease.